AbbVie | ABBV - Sales Revenues


AbbVie reported $15B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Abbott USD 11.16B 300M Mar/2026
ALKERMES USD 392.91M 8.41M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Infinity Pharmaceuticals USD 583K 148K Jun/2023
J&J USD 24.1B 500M Mar/2026
Medtronic USD 9.8B 800M Mar/2026
Merck USD 16.29B 110M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
UCB EUR 4.25B 764M Dec/2025
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Zoetis USD 2.3B 100M Mar/2026